Sepsis Therapeutics: Market Research Report

Date: August 22, 2011
Pages: 188
Price:
US$ 3,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S6C8A3BE9FBEN
Leaflet:

Download PDF Leaflet

Sepsis Therapeutics: Market Research Report
This report analyzes the worldwide markets for Sepsis Therapeutics in US$ Million.

Analytics refer to sales of drugs used in the direct treatment of severe sepsis/septic shock.

The report provides separate comprehensive analytics for the US, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 33 companies including many key and niche players such as Agennix AG, AstraZeneca Plc, Artisan Pharma, Atox Bio, Inc., CytoGenix, Inc., Chong Kun Dang Pharmaceutical Corporation, Daiichi-Sankyo Company, Ltd., Endacea, Inc., Eli Lilly and Company, Medinox, Inc., and NexBio, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
1.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

2.INDUSTRY OVERVIEW

A Prelude
Snapshots

Table 1. Annual Incidence of Sepsis in the US and EU-27

Sepsis Treatment: An Untapped Market
Challenges Facing Sepsis Treatment
Lack of Awareness
Efforts to Enhance Awareness
Delayed Start of Treatment
Diagnostic Tools For Faster Treatment
Sepsis in Neonates: A Major Challenge

3.SEPSIS - AN INTRODUCTION

Sepsis - A Leading Killer
Risk Profile
Most Vulnerable Group: New Born and Elderly
A Growing Threat in Hospital Environment
Types of Sepsis

SIRS

Uncomplicated Sepsis
Severe Sepsis
Septic Shock
Septicemia
Bacteremia
Mortality Rates

Table 2. 28-Day Mortality Rate: Progression from Infection to Septic Shock

Symptoms to Identify Sepsis Patients
General Symptoms in Sepsis Patients
Symptoms Specific to Source of Infection
Biological Changes in Sepsis Patients
Organ Dysfunction Symptoms in Acute Cases
Common Sources of Sepsis

Table 3. Primary Site of Infection Affected by Sepsis (includes corresponding Graph/Chart)

Stages of Sepsis’ Progression
Treatment of Sepsis
General Approaches for Treatment of Severe Sepsis and Septic Shock
First Line of Treatment
Identifying Infection Source
Overview of Traditional Treatment Approaches
Corticosteroids
Immunoglobulins
Anticoagulants
Neonatal Sepsis

4.DRUGS FOR SEPSIS TREATMENT: AN OVERVIEW

Xigris - The Only Approved Treatment for Sepsis
Declining Sales: A Cause of Concern for Xigris Brand
PROWESS Study
Artisan Pharma’s ART 123
AstraZeneca’s CytoFab™
Agennix’s Talactoferrin
Chong Kun Dang Pharmaceutical’s CKD-712
Eisai’s Eritoran
Takeda’s TAK-242
Current Development Status of Select Sepsis Drugs
Primary Completion Dates of Select Sepsis Therapeutics

5.STRATEGIC CORPORATE DEVELOPMENTS

Eisai’s Eritoran Fails Phase III Trial
Rhode Island Hospital Identifies New Protein
Agennix Offers Data from Talactoferrin Phase II Trial
Nycomed Acquires Majority Interest in Guangdong Techpool Bio-Pharma
Tianjin Chase Collaborates with Chongging Southwest Hospital for Developing Sepsis Drug
Artisan Pharma Announces Phase IIb Study of ART-123
AstraZeneca Commences Phase IIb Trials for CytoFab™
Medinox Collaborates with Orient Europharma for NOX-100
GPC Biotech Signs Business Combination Agreement with Agennix
Fast-Track Drugs & Biologics and Atox Bio Enter into Collaboration
Sirius Genomics Enters into Agreement with Assistance Publique-Hopitaux de Paris
Takeda Discontinues Compound Development for Severe Sepsis
BTG Acquires Protherics
Galapagos and UCL Sign Agreement
Artisan Pharma Receives Approval for ART-123 in Japan

6.FOCUS ON SELECT PLAYERS

Agennix AG (Germany)
AstraZeneca Plc (UK)
Artisan Pharma (US)
Atox Bio, Inc. (US)
CytoGenix, Inc. (US)
Chong Kun Dang Pharmaceutical Corporation (Korea)
Daiichi-Sankyo Company, Ltd. (Japan)
Endacea, Inc. (US)
Eli Lilly and Company (US)
Medinox, Inc.
NexBio, Inc. (US)

7.GLOBAL MARKET PERSPECTIVE

Table 4. World Recent Past, Current and Future Analysis for Sepsis Drugs by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 5. World Historic Review for Sepsis Drugs by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 6. World 15-Year Perspective for Sepsis Drugs by Geographic Region – Percentage Breakdown of Value Sales for US and Rest of World Markets for Years 2003, 2010, and 2017 (includes corresponding Graph/Chart)

8.THE UNITED STATES

A. MARKET ANALYSIS

Outlook
Snapshots
Rising Incidence of Healthcare Infections
Sepsis: A Leading Cause of Mortality in the US

Table 7. Incidence and Mortality Rate of Select Diseases in the US
Table 8. Number of Deaths Per Annum of Select Diseases in the US

An Economic Burden
Risk of Sepsis in Neonates
Reimbursement Scenario

B. MARKET ANALYTICS

Table 9. US Recent Past, Current and Future Analysis for Sepsis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 10. US Historic Review for Sepsis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

9.REST OF WORLD

A. MARKET ANALYSIS

Outlook
Canada

Table 11. Mortality Rate (%) of Select Conditions in Canada

Europe
United Kingdom
Drotrecogin Alfa (Activated): Recommended for High-Risk Sepsis Patients
The Netherlands
Poland

B. MARKET ANALYTICS

Table 12. Rest of World Recent Past, Current and Future Analysis for Sepsis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 13. Rest of World Historic Review for Sepsis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Total Companies Profiled: 33 (including Divisions/Subsidiaries - 35)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East
Skip to top


Sepsis - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 240 pages

Ask Your Question

Sepsis Therapeutics: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: